FDA report of Lidocaine injection recall due to visible particulates

0

FAD report “Hospira, Inc. will initiate a voluntary recall of one lot of 1% Lidocaine HCI Injection, USP, 10mg/mL, 30 mL single dose, Preservative – Free to the user level due to a confirmed customer report of orange and black particulate within the solution and embedded within the glass vial. Hospira has identified the particulate as iron oxide. Risk factors associated with the particulate include the potential for particulate to be injected and/or a delay in therapy.”

Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).

Main page

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.